Eikon Therapeutics (EIKN) sees Column Group funds convert and buy shares

Rhea-AI Filing Summary

Entities affiliated with The Column Group reported sizable ownership changes in Eikon Therapeutics, Inc. (EIKN) tied to the company’s initial public offering. On February 6, 2026, multiple funds converted preferred stock into common and also bought additional shares.

The Column Group IV, LP, IV-A, LP and Opportunity III, LP converted Series A, A-1, C-1 and D preferred shares into common stock at an approximate 0.1340878-to-1 ratio and now hold indirect positions including 4,312,139, 148,840 and 1,319,164 common shares, respectively. On the same date, these entities also made open-market purchases of 1,437,323, 49,556 and 630,881 common shares at $18 per share. The filing states that the reporting persons disclaim beneficial ownership beyond their pecuniary interest.

Insights

Equity ownership and governance analyst

Column Group funds convert preferred into Eikon common and add shares at $18.

The filing shows several Column Group funds converting multiple preferred series into Eikon Therapeutics common stock immediately before the IPO closing. The stated conversion rate is about 0.1340878 common share per preferred share, turning pre-IPO securities into listed equity.

In addition, The Column Group IV, LP, IV-A, LP and Opportunity III, LP executed open-market purchases of 1,437,323, 49,556 and 630,881 common shares at $18 per share, bringing their indirect holdings to 4,312,139, 148,840 and 1,319,164 shares as of February 6, 2026. The filing notes that various general partner entities and individuals may be deemed to share voting and investment power but disclaim beneficial ownership beyond their pecuniary interests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Column Group IV GP, LP

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		C(1)		1,296,629	A	(1)	1,360,320	I	By The Column Group IV, LP(2)
Common Stock	02/06/2026		C(1)		1,403,568	A	(1)	2,763,888	I	By The Column Group IV, LP(2)
Common Stock	02/06/2026		C(1)		110,928	A	(1)	2,874,816	I	By The Column Group IV, LP(2)
Common Stock	02/06/2026		C(1)		44,249	A	(1)	47,601	I	By The Column Group IV-A, LP(3)
Common Stock	02/06/2026		C(1)		47,898	A	(1)	95,499	I	By The Column Group IV-A, LP(3)
Common Stock	02/06/2026		C(1)		3,785	A	(1)	99,284	I	By The Column Group IV-A, LP(3)
Common Stock	02/06/2026		C(1)		688,283	A	(1)	688,283	I	By The Column Group Opportunity III, LP(4)
Common Stock	02/06/2026		P		1,437,323	A	$18	4,312,139	I	By The Column Group IV, LP(2)
Common Stock	02/06/2026		P		49,556	A	$18	148,840	I	By The Column Group IV-A, LP(3)
Common Stock	02/06/2026		P		630,881	A	$18	1,319,164	I	By The Column Group Opportunity III, LP(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	02/06/2026		C(1)			9,670,000	(1)	(1)	Common Stock	1,296,629	(1)	0	I	By The Column Group IV, LP(2)
Series A Preferred Stock	(1)	02/06/2026		C(1)			330,000	(1)	(1)	Common Stock	44,249	(1)	0	I	By The Column Group IV-A, LP(3)
Series A-1 Preferred Stock	(1)	02/06/2026		C(1)			10,467,526	(1)	(1)	Common Stock	1,403,568	(1)	0	I	By The Column Group IV, LP(2)
Series A-1 Preferred Stock	(1)	02/06/2026		C(1)			357,216	(1)	(1)	Common Stock	47,898	(1)	0	I	By The Column Group IV-A, LP(3)
Series C-1 Preferred Stock	(1)	02/06/2026		C(1)			827,278	(1)	(1)	Common Stock	110,928	(1)	0	I	By The Column Group IV, LP(2)
Series C-1 Preferred Stock	(1)	02/06/2026		C(1)			28,229	(1)	(1)	Common Stock	3,785	(1)	0	I	By The Column Group IV-A, LP(3)
Series D Preferred Stock	(1)	02/06/2026		C(1)			5,133,076	(1)	(1)	Common Stock	688,283	(1)	0	I	By The Column Group Opportunity III, LP(4)

1. Name and Address of Reporting Person^*

Column Group IV GP, LP

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Column Group IV-A, LP

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Column Group IV, LP

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Column Group Opportunity III, LP

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Column Group Opportunity III GP, LP

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

TCG Opportunity III GP, LLC

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kutzkey Tim

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Svennilson Peter

(Last) (First) (Middle)

1 LETTERMAN DR., BLDG D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date

2. The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

3. The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

4. The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

	/s/ The Column Group IV GP, LP, /s/ James Evangelista, Attorney-in-Fact	02/09/2026
	/s/ The Column Group IV-A, LP. by The Column Group IV GP, LP, its general partner, /s/ James Evangelista, Attorney-in-Fact	02/09/2026
	/s/ The Column Group IV, LP by The Column Group IV GP, LP, its general partner /s/ James Evangelista, Attorney-in-Fact	02/09/2026
	/s/ The Column Group Opportunity III, LP, by The Column Group Opportunity GP, LP its general partner, by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista, Attorney-in-Fact	02/09/2026
	/s/ The Column Group Opportunity III GP, LP., by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista, Attorney-in-Fact	02/09/2026
	/s/ TCG Opportunity III GP, LLC, /s/ James Evangelista, Attorney-in-Fact	02/09/2026
	/s/James Evangelista, as attorney-in-fact for Tim Kutzkey	02/09/2026
	/s/James Evangelista, as attorney-in-fact for Peter Svennilson	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Column Group entities report for Eikon Therapeutics (EIKN)?

Column Group–affiliated funds reported converting several series of preferred stock into Eikon Therapeutics common shares and buying additional common stock on February 6, 2026. These actions increased their indirect common stock holdings across multiple funds at the time of the company’s initial public offering.

How many Eikon Therapeutics shares did Column Group IV, LP hold after the Form 4 transactions?

After the reported transactions, The Column Group IV, LP indirectly held 4,312,139 Eikon Therapeutics common shares. This reflects both preferred stock conversions into common shares and an open-market purchase of 1,437,323 common shares at $18 per share completed on February 6, 2026.

What was the conversion rate from Eikon preferred stock to common stock in this Form 4?

Each share of Eikon Therapeutics Series A, A-1, B-1, C, C-1 and D preferred stock automatically converted into approximately 0.1340878 common shares. This automatic conversion occurred immediately prior to the closing of Eikon’s initial public offering and applied to the preferred holdings disclosed in the filing.

Which Column Group funds purchased Eikon Therapeutics common stock at $18 per share?

The Column Group IV, LP, The Column Group IV-A, LP and The Column Group Opportunity III, LP purchased Eikon Therapeutics common stock at $18 per share. They bought 1,437,323, 49,556 and 630,881 shares respectively on February 6, 2026, in open-market or private transactions.

Do the reporting persons claim full beneficial ownership of the Eikon shares in this filing?

The reporting persons state that the shares are directly held by Column Group investment partnerships and related entities. They may be deemed to share voting and investment power but each disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest in those holdings.

How did the preferred stock held by Column Group Opportunity III, LP change in this Eikon filing?

Column Group Opportunity III, LP reported converting 5,133,076 shares of Series D preferred stock into Eikon Therapeutics common shares. This conversion produced 688,283 common shares, and after the transaction the fund is shown as indirectly owning 688,283 common shares as of February 6, 2026.